navan
/
Daily-Dose
mirror of https://github.com/navanchauhan/Daily-Dose.git
1
0
Fork 0
Code Issues Projects Releases Wiki Activity

Added daily report

This commit is contained in:
Navan Chauhan 2022-07-19 13:04:52 +00:00
parent ae90116e5a
commit 8dad549918
3 changed files with 707 additions and 2 deletions
Show Stats Download Patch File Download Diff File Expand all files Collapse all files

192
archive-covid-19/19 July, 2022.html Normal file
View File

@ -0,0 +1,192 @@
<!DOCTYPE html>
<html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
<meta charset="utf-8"/>
<meta content="pandoc" name="generator"/>
<meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
<title>19 July, 2022</title>
<style type="text/css">
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
span.underline{text-decoration: underline;}
div.column{display: inline-block; vertical-align: top; width: 50%;}
</style>
<title>Covid-19 Sentry</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
<body>
<h1 data-aos="fade-down" id="covid-19-sentry">Covid-19 Sentry</h1>
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
<ul>
<li><a href="#from-preprints">From Preprints</a></li>
<li><a href="#from-clinical-trials">From Clinical Trials</a></li>
<li><a href="#from-pubmed">From PubMed</a></li>
<li><a href="#from-patent-search">From Patent Search</a></li>
</ul>
<h1 data-aos="fade-right" id="from-preprints">From Preprints</h1>
<ul>
<li><strong>Corpus-based Studies of Metaphor: An Overview</strong> -
<div>
The researchers performed this systematic review to offer insights into the trend of the corpus-based approach in studying metaphor in recent years and investigate the potential gaps and under-researched areas in the past literature on the topic. Two research databases, namely Google Scholar and Academics, were explored to collect data. The analysis of metaphor-related research studies published between 2015 and 2020 revealed more than 78 studies dealing with the topic of investigation. After the screening process, 23 studies that met the research criteria were retained for analysis. The selected articles were further analyzed using the two-step analysis involving quantitative and qualitative approaches, i.e., descriptive statistics, and thematic analysis. The findings revealed that metaphor studies employing the corpus approach tend to use existing corpus like the Reference Corpus instead of a specialized corpus. In addition, metaphor studies in this review centered more on written discourse than spoken data. Furthermore, there is also a lack of information on the corpus tool employed in the examined studies. Meanwhile, the thematic analysis unearthed potential gaps and under-researched areas, such as limited studies on COVID-19 metaphor even though the outbreak had started at the end of 2019. Future studies on this research could include more specialized corpora, specifically in the under-researched topics, to fill in the gaps in this area of study.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://osf.io/preprints/socarxiv/mf47g/" target="_blank">Corpus-based Studies of Metaphor: An Overview</a>
</div></li>
<li><strong>The Landscape of Neutralizing antibodies (NAb): Production, Mechanisms of Action (MOA), FDA approved-antibodies, and Functional assay</strong> -
<div>
A neutralizing antibody (NAb) is an antibody that is responsible for defending cells from pathogens, which are organisms that cause disease. They are made by B-cells in the bone marrow, and their production is triggered by both infections and vaccinations against infections. Regarding neutralizing antibody activity, Neutralization can be achieved through four main mechanisms, which are summarized in this article. FDA has approved many neutralizing antibodies (NAb), and GeneMedi provides the corresponding antibodies targeting Pathogens including SARS-CoV-2, Human Immunodeficiency Virus (HIV), and Hepatitis B virus (HBV), Rabies virus, Respiratory syncytial virus (RSV), and so on. This article described the Production, Mechanisms of Action (MOA), FDA approved-antibodies, and Functional assay of Neutralizing antibodies (NAb).
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://osf.io/axuc2/" target="_blank">The Landscape of Neutralizing antibodies (NAb): Production, Mechanisms of Action (MOA), FDA approved-antibodies, and Functional assay</a>
</div></li>
<li><strong>Identification of a Papain-Like Protease Inhibitor with Potential for Repurposing in Combination with an Mpro Protease Inhibitor for Treatment of SARS-CoV-2</strong> -
<div>
SARS-CoV-2 requires two cysteine proteases for viral polypeptide processing to allow maturation and replication: the 3Clike protease also known as the Main protease (Mpro) and the papain-like protease (PLpro). In addition to its critical role in viral replication, PLpro removes post-translational modifications like ubiquitin and interferon-stimulated gene product 15 (ISG15) from host proteins through its deubiquitinase domain, leading to host immunosuppression and increased ability of the virus to evade the host antiviral immune response. Through screening of a custom clinical compound library, we identified eltrombopag (DDL701), a thrombopoietin receptor antagonist, as having PLpro inhibitory activity that is sustained in the presence of the Mpro inhibitor nirmatrelvir. DDL701 also suppressed both the deubiquitinase and ISG15 cleavage activities of PLpro. In addition, DDL701 partially restored interferon-{beta} induction, an element of the host immune response, in an in vitro model system. Further, modeling and docking studies suggest DDL701 interacts with the active site region of the PLpro enzyme and pilot pharmacokinetic studies indicate it is brain permeable. DDL701 is already approved for treatment of thrombocytopenia and has previously been shown to achieve human plasma levels after oral dosing that is above the IC50 needed for it to exert its PLpro inhibitory activity in vivo. In addition, it has also been reported to have antiviral efficacy against SARS-CoV-2. DDL-701 thus represents a drug that can immediately be repurposed and undergo clinical evaluation as a PLpro inhibitor that may be most effectively used in a protease inhibitor cocktail with an Mpro inhibitor such as nirmatrelvir (Paxlovid) for the treatment of COVID19.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2022.07.18.500363v1" target="_blank">Identification of a Papain-Like Protease Inhibitor with Potential for Repurposing in Combination with an Mpro Protease Inhibitor for Treatment of SARS-CoV-2</a>
</div></li>
<li><strong>In silico repurposed drugs against monkeypox virus</strong> -
<div>
Monkeypox is an emerging epidemic of concern. The disease is caused by the monkeypox virus and an increasing global incidence with a 2022 outbreak that has spread to Europe amid the COVID-19 pandemic. The new outbreak is associated with novel, previously undiscovered mutations and variants. Currently the US Food and Drug Administration (FDA) approved poxvirus treatment involves use of tecovirimat. However, there is limited pharmacopoeia otherwise, and limited research interest in monkeypox. In this study, virtual screening and molecular dynamics were employed to explore the potential repurposing of multiple drugs previously approved by the FDA or other jurisdictions for other applications. Several drugs are predicted to tightly bind to viral proteins which are crucial in viral replication, including molecules which show high potential for binding the monkeypox D13L capsid protein, whose inhibition has previously been demonstrated to suppress viral replication.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2022.07.17.500371v1" target="_blank">In silico repurposed drugs against monkeypox virus</a>
</div></li>
<li><strong>Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccination</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
A large proportion of the global population received a single dose of the Ad26.COV2.S coronavirus disease-2019 (COVID-19) vaccine as priming vaccination, which was shown to provide protection against moderate to severe COVID-19. However, the emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants that harbor immune-evasive mutations in the spike protein led to the recommendation of booster vaccinations after Ad26.COV2.S priming. Recent studies showed that heterologous booster vaccination with an mRNA-based vaccine following Ad26.COV2.S priming leads to high antibody levels. However, how heterologous booster vaccination affects other functional aspects of the immune response remains unknown. Here, we performed immunological profiling on samples obtained from Ad26.COV2.S-vaccinated individuals before and after a homologous (Ad26.COV2.S) or heterologous (mRNA-1273 or BNT162b2) booster vaccination. Both homologous and heterologous booster vaccination increased antibodies with multiple functionalities towards ancestral SARS-CoV-2, the Delta and Omicron BA.1 variants. Especially, mRNA-based booster vaccination induced high levels of neutralizing antibodies and antibodies with various Fc-mediated effector functions such as antibody-dependent cellular cytotoxicity and phagocytosis. In contrast, T cell responses were similar in magnitude following homologous or heterologous booster vaccination, and retained functionality towards Delta and Omicron BA.1. However, only heterologous booster vaccination with an mRNA-based vaccine led to the expansion of SARS-CoV-2-specific T cell clones, without an increase in the breadth of the T cell repertoire as assessed by T cell receptor sequencing. In conclusion, we show that Ad26.COV2.S priming vaccination provides a solid immunological base for heterologous boosting with an mRNA-based COVID-19 vaccine, increasing humoral and cellular responses targeting newly emerging variants of concern.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.07.15.22277639v1" target="_blank">Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccination</a>
</div></li>
<li><strong>Loss of SARS-CoV-2 Seropositivity among Healthy Young Adults over Seven Months</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Objective: We conducted a longitudinal study to estimate immunity produced in response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among university students over seven months. Methods: All participants were attending a public university and resided in Pitt County, North Carolina. University students enrolled weekly for 10 weeks between August 26, 2020 and October 28, 2020, resulting in 136 young adults completing at least one study visit by November 17, 2020. Enrolled students completed an online survey and nasal swab collection at two week intervals and monthly blood collection between August 26, 2020 and March 31, 2021. Results: Amongst 695 serum samples tested during follow-up, the prevalence of a positive result for anti-nucleocapsid antibodies (N-IgG) was 9.78%. In 22 students with more than one positive N-IgG serum sample, 68.1% of group had decline of N-IgG below positive threshold over 140 days. Anti-spike antibodies were detected in all 11 vaccinated students who were vaccinated during March 2021. Conclusions: In healthy young adults, N-IgG wanes below detectable threshold within five months. S-IgG remained consistently elevated months after infection, and significantly increased after vaccination.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.07.15.22277688v1" target="_blank">Loss of SARS-CoV-2 Seropositivity among Healthy Young Adults over Seven Months</a>
</div></li>
<li><strong>Model training periods impact estimation of COVID-19 incidence from wastewater viral loads</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
<b>Background:</b> Wastewater-based epidemiology (WBE) has been deployed broadly as an early warning tool for emerging COVID-19 outbreaks. WBE can inform targeted interventions and identify communities with high transmission, enabling quick and effective response. As wastewater becomes an increasingly important indicator for COVID-19 transmission, more robust methods and metrics are needed to guide public health decision making. <b>Objectives:</b> The aim of this research was to develop and implement a mathematical framework to infer incident cases of COVID-19 from SARS-CoV-2 levels measured in wastewater. We propose a classification scheme to assess the adequacy of model training periods based on clinical testing and assess the sensitivity of model predictions to training periods. <b>Methods:</b> We present a Bayesian deconvolution method and linear regression to estimate COVID-19 cases from wastewater data. We described an approach to characterize adequacy in testing during specific time periods and provided evidence to highlight the importance of model training periods on the projection of cases. We estimated the effective reproductive number (<i>Re</i>) directly from observed cases and from the reconstructed incidence of cases from wastewater. The proposed modeling framework was applied to three Northern California communities served by distinct wastewater treatment plants. <b>Results:</b> Both deconvolution and linear regression models consistently projected robust estimates of prevalent cases and <i>Re</i> from wastewater influent samples when assuming training periods with adequate testing. Case estimates from models that used poorer-quality training periods consistently underestimated observed cases. <b>Discussion:</b> Wastewater surveillance data requires robust statistical modeling methods to provide actionable insight for public health decision-making. We propose and validate a modeling framework that can provide estimates of prevalent COVID-19 cases and <i>Re</i> from wastewater data that can be used as tool for disease surveillance including quality assessment for potential training data.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.07.16.22276772v1" target="_blank">Model training periods impact estimation of COVID-19 incidence from wastewater viral loads</a>
</div></li>
<li><strong>The association of typical and atypical symptoms on in-hospital mortality of older adults with COVID-19: a multicentre cohort study</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Atypical disease presentations are common in older adults with COVID-19. The objective of this study was to determine the prevalence of atypical and typical symptoms in older adults with COVID-19 through progressive pandemic waves and the association of these symptoms with in-hospital mortality. This retrospective cohort study included consecutive adults aged over 65 years with confirmed COVID-19 infection who were admitted to seven hospitals in Toronto, Canada from March 1, 2020 to June 30, 2021. The median age for the 1786 patients was 78.0 years and 847 (47.5%) were female. Atypical symptoms (as defined by geriatric syndromes) occurred in 1187 patients (66.5%), but rarely occurred in the absence of other symptoms (n=106, 6.2%). The most common atypical symptoms were anorexia (n=598, 33.5%), weakness (n=519, 23.9%), and delirium (n=449, 25.1%). Dyspnea (adjusted odds ratio [aOR] 2.05, 95% confidence interval [CI] 1.62-2.62), tachycardia (aOR 1.87, 95% CI 1.14-3.04), and delirium (aOR 1.52, 95% CI 1.18-1.96) were independently associated with in-hospital mortality. In a cohort of older adults hospitalized with COVID-19 infection, atypical presentations frequently overlapped with typical symptoms. Further research should be directed at understanding the cause and clinical significance of atypical presentations in older adults.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.07.16.22277716v1" target="_blank">The association of typical and atypical symptoms on in-hospital mortality of older adults with COVID-19: a multicentre cohort study</a>
</div></li>
<li><strong>Slow waning of antibodies following a third dose of BNT162b2 in adults who had previously received two doses of inactivated vaccine</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Introduction: Third doses of COVID-19 vaccination provide an important boost to immunity, reducing the risk of symptomatic infection and the risk of severe disease. Third doses have been particularly important for improving protection against variants. However, waning of clinical protection particularly against Omicron has been noted after receipt of third doses. Methods: We administered BNT162b2 as a third dose to adults aged ≥30 years who had previously received two doses of inactivated vaccination. We collected blood before the third dose and again after one month and six months, and tested sera using a spike receptor binding domain IgG enzyme-linked immunosorbent assay, a surrogate virus neutralization test, and live virus plaque reduction neutralization assay against ancestral virus and Omicron BA.2. Results: We administered BNT162b2 as a third dose to 314 adults. We found robust antibody responses to the ancestral strain at six months after receipt of BNT162b2. Antibody responses to Omicron BA.2 were weaker after the third dose and had declined to a low level by six months. From a small number of participants we observed that natural infection or a fourth dose of vaccination generated similar antibody levels against ancestral virus, but infection generated higher antibody level against Omicron BA.2 than vaccination, suggesting a potential advantage in the breadth of antibody response from hybrid immunity. Conclusions: While antibody levels against the ancestral strain remained robust at six months after the third dose, antibody levels against Omicron BA.2 had fallen to low levels suggesting the potential benefits of a fourth dose.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.07.18.22277741v1" target="_blank">Slow waning of antibodies following a third dose of BNT162b2 in adults who had previously received two doses of inactivated vaccine</a>
</div></li>
<li><strong>Exploring Impacts to COVID-19 Herd Immunity Thresholds Under Demographic Heterogeneity that Lowers Vaccine Effectiveness</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The COVID-19 pandemic has caused severe health, economic, and societal impacts across the globe. Although highly efficacious vaccines were developed at an unprecedented rate, the heterogeneity in vaccinated populations has reduced the ability to achieve herd immunity. Specifically, as of Spring 2022, the 0-4 year-old population is still unable to be vaccinated and vaccination rates across 5-11 year olds are low. Additionally, vaccine hesitancy for older populations has further stalled efforts to reach herd immunity thresholds. This heterogeneous vaccine landscape increases the challenge of anticipating disease spread in a population. We developed an age-structured Susceptible-Infectious-Recovered-type mathematical model to investigate the impacts of unvaccinated subpopulations on herd immunity. The model considers two types of undervaccination: age-related and behavior-related, by incorporating four age groups based on available FDA-approved vaccines. The model accounts for two different types of vaccines, mRNA (e.g., Pfizer, Moderna) and vector (e.g., Johnson and Johnson), as well as their effectiveness. Our goal is to analyze different scenarios to quantify which subpopulations and vaccine characteristics (e.g., rate or efficacy) most impact infection levels in the United States, using the state of New Mexico as an example.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.07.18.22277763v1" target="_blank">Exploring Impacts to COVID-19 Herd Immunity Thresholds Under Demographic Heterogeneity that Lowers Vaccine Effectiveness</a>
</div></li>
<li><strong>A pilot surveillance report of SARS-CoV-2 rapid antigen test results among volunteers in Germany, 1st week of July 2022</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
We hypothesized that reported SARS-CoV-2 infection numbers are underestimated and piloted a point prevalence by rapid antigen testing in the VACCELERATE volunteer registry. Between July-1 and July-7, 2022, 7/419 (1.67%) tests were positive. Compared to reports of the German Federal Government, our results suggest a 2.39-fold higher prevalence. Our findings imply that the actual prevalence of SARS-CoV-2 may be higher than detected by current surveillance systems, so that current pandemic surveillance and testing strategies need to be adapted.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.07.18.22277744v1" target="_blank">A pilot surveillance report of SARS-CoV-2 rapid antigen test results among volunteers in Germany, 1st week of July 2022</a>
</div></li>
<li><strong>COVID-19 vaccine effectiveness against progression to in-hospital mortality — Zambia, 2021-2022</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Background: COVID-19 vaccines are highly effective for reducing severe disease and mortality. However, vaccine effectiveness data is limited from sub-Saharan Africa, where SARS-CoV-2 epidemiology has differed from other regions. We report COVID-19 vaccine effectiveness against progression to in-hospital mortality in Zambia. Methods: We conducted a retrospective cohort study among admitted patients at eight COVID-19 treatment centers across Zambia during April 2021 through March 2022. Patient demographic and clinical information including vaccination status and in-patient disposition (discharged or died) were collected. Multivariable logistic regression was used to assess the odds of in-hospital mortality by vaccination status, adjusted for age, sex, number of comorbid conditions, disease severity, and COVID-19 treatment center. Vaccine effectiveness was calculated from the adjusted odds ratio. Results: Among 1,653 patients with data on their vaccination status and hospitalization outcome, 365 (22.1%) died. For patients who had received ≥1 vaccine dose before hospital admission, 22 (9.3%) died compared with 343 (24.2%) among unvaccinated patients (p &lt;0.01). The median time since receipt of a first vaccine dose was 52.5 days (IQR: 28-107). Vaccine effectiveness for progression to in-hospital mortality among hospitalized patients was 64.8% (95% CI: 42.3-79.4%). Conclusions: Among patients admitted to COVID-19 treatment centers in Zambia, those who were vaccinated had lower odds of in-hospital mortality compared to those who were unvaccinated. These data are consistent with evidence from other countries demonstrating benefit of COVID-19 vaccination. Vaccination is a critical tool for reducing the consequences of COVID-19 in Zambia.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.07.18.22277749v1" target="_blank">COVID-19 vaccine effectiveness against progression to in-hospital mortality — Zambia, 2021-2022</a>
</div></li>
<li><strong>A simple SEIR-V model to estimate COVID-19 prevalence and predict SARS-CoV-2 transmission using wastewater-based surveillance data</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Wastewater-based surveillance (WBS) has been widely used as a public health tool to monitor SARS-CoV-2 transmission. However, epidemiological inference from WBS data remains understudied and limits its application. In this study, we have established a quantitative framework to estimate COVID-19 prevalence and predict SARS-CoV-2 transmission through integrating WBS data into an SEIR-V model. We conceptually divide the individual-level viral shedding course into exposed, infectious, and recovery phases as an analogy to the compartments in population-level SEIR model. We demonstrated that the temperature effect on viral losses in the sewer can be straightforwardly incorporated in our framework. Using WBS data from the second wave of the pandemic (Oct 02, 2020-Jan 25, 2021) in the Great Boston area, we showed that the SEIR-V model successfully recapitulates the temporal dynamics of viral load in wastewater and predicts the true number of cases peaked earlier and higher than the number of reported cases by 16 days and 8.6 folds (R=0.93), respectively. This work showcases a simple, yet effective method to bridge WBS and quantitative epidemiological modeling to estimate the prevalence and transmission of SARS-CoV-2 in the sewershed, which could facilitate the application of wastewater surveillance of infectious diseases for epidemiological inference and inform public health actions.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.07.17.22277721v1" target="_blank">A simple SEIR-V model to estimate COVID-19 prevalence and predict SARS-CoV-2 transmission using wastewater-based surveillance data</a>
</div></li>
<li><strong>Pandemic modelling for regions implementing an elimination strategy</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
During the COVID-19 pandemic, some countries, such as Australia, China, Iceland, New Zealand, Thailand and Vietnam, successfully implemented an elimination strategy. Until June 2021, Atlantic Canada and Canada9s territories had also experienced prolonged periods with few SARS-CoV-2 community cases. Such regions had a need for epidemiological models that could assess the risk of SARS-CoV-2 outbreaks, but most existing frameworks are applicable to regions where SARS-CoV-2 is spreading in the community, and so it was necessary to adapt existing frameworks to meet this need. We distinguish between infections that are travel-related and those that occur in the community, and find that in Newfoundland and Labrador (NL), Nova Scotia, and Prince Edward Island the mean percentage of daily cases that were travel-related was 80% or greater (July 1, 2020 – May 31, 2021). We show that by December 24, 2021, the daily probability of an Omicron variant community outbreak establishing in NL was near one, and nearly twice as high as the previous high, which occurred in September 2021 when the Delta variant was dominant. We evaluate how vaccination and new variants might affect hypothetical future outbreaks in Mt. Pearl, NL. Our modelling framework can be used to evaluate alternative plans to relax public health restrictions when high levels of vaccination are achieved in regions that have implemented an elimination strategy.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.07.18.22277695v1" target="_blank">Pandemic modelling for regions implementing an elimination strategy</a>
</div></li>
<li><strong>COVID-19 Vaccine Booster Dose Willingness Among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional Study</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Background: Vaccination has been effective in preventing COVID-19 infections and related mortality. However, waning immunity after the two-dose vaccination prompted health authorities to recommend a third dose of COVID-19 vaccine to boost immunity. The aim of our study was to assess willingness to receive a third (booster) dose among patients with IBD. Methods: A cross-sectional study was performed at a tertiary care inflammatory bowel disease center. Patients were recruited at the infusion room from January 1st, 2022, until March 31st, 2022. The primary outcome was the prevalence of BNT162b2 third (booster) dose in infliximab or vedolizumab treated patients with IBD. The secondary outcome evaluated whether the prevalence of BNT162b2 third (booster) dose differed based on type of COVID-19 vaccine, gender, age, type of biologic therapy and citizenship. Results: In total, 499 patients with IBD were included in this study. The median age was 34.5 years, and 60% had ulcerative colitis (UC). Among the study participants, 302 (60.5%) patients were vaccinated with BNT162b2, and 197 (39.5%) were vaccinated with ChAdOx1 nCoV-19. Of the total number of participants, 400 (80.2%) were receiving infliximab, and 99 (19.8%) were receiving vedolizumab. Overall, 290 (58.1%) of the included patients were willing to receive the third (booster) dose. Patients vaccinated with BNT162b2 were more likely to receive booster dose compared to patients vaccinated with ChAdOx1 nCoV-19 [201 (66.5%) vs 101 (33.5%), p = 0.014]. Infliximab-treated patients were more likely to receive booster dose compared to patients receiving vedolizumab [310 (77.5%) vs 62 (62.6%), p = 0.002]. There was no statistical difference in willingness to receive booster dose in terms of age, nationality, or gender. Conclusion: The percentage of patients with IBD willing or have received a third (booster) dose of BNT162b2 vaccine was lower compared to general population. In addition, patients who received two doses of BNT162b2 vaccines were more likely to receive a third (booster) dose compared to patients who received ChAdOx1 nCoV-19. Patients treated with infliximab were more likely to receive a third (booster) dose of COVID-19 vaccine.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.07.18.22277757v1" target="_blank">COVID-19 Vaccine Booster Dose Willingness Among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional Study</a>
</div></li>
</ul>
<h1 data-aos="fade-right" id="from-clinical-trials">From Clinical Trials</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Bank of Human Leukocytes From COVID-19 Convalescent Donors With an Anti-SARS-CoV-2 Cellular Immunity</strong> - <b>Condition</b>:   COVID-19<br/><b>Intervention</b>:   Other: Generation of a biobank allowing the cryopreservation of leucocytes from COVID19 convalescent donors<br/><b>Sponsor</b>:   Central Hospital, Nancy, France<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients</strong> - <b>Condition</b>:   Severe COVID-19<br/><b>Interventions</b>:   Biological: Coronavirus-2-specific T cells;   Other: standard of care (SOC)<br/><b>Sponsors</b>:   George Papanicolaou Hospital;   General Hospital Of Thessaloniki Ippokratio<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Randomised, Multi-centre, Double-blind, Phase 3 Study to Observe the Effectiveness, Safety and Tolerability of Molnupiravir Compared to Placebo Administered Orally to High-risk Adult Outpatients With Mild COVID-19 Receiving Local Standard of Care in South Africa</strong> - <b>Condition</b>:   COVID-19<br/><b>Intervention</b>:   Drug: Molnupiravir 200 mg<br/><b>Sponsors</b>:   University of Witwatersrand, South Africa;   Bill and Melinda Gates Foundation<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Drug: FB2001;   Drug: FB2001 placebo<br/><b>Sponsor</b>:   Frontier Biotechnologies Inc.<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Engaging Staff to Improve COVID-19 Vaccination Response at Long-Term Care Facilities</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Behavioral: Full Intervention;   Other: Enhanced Usual Care<br/><b>Sponsors</b>:   Kaiser Permanente;   Patient-Centered Outcomes Research Institute;   Global Alliance to Prevent Prematurity and Stillbirth (GAPPS)<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Study to Evaluate the Efficacy of PanCytoVir™ for the Treatment of Non-Hospitalized Patients With COVID-19 Infection</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Drug: PanCytoVir™ (probenecid);   Drug: Placebo<br/><b>Sponsor</b>:   TrippBio, Inc.<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Value of Montelukast as a Potential Treatment of Post COVID-19 Persistent Cough</strong> - <b>Condition</b>:   Post COVID-19<br/><b>Intervention</b>:   Drug: Montelukast Sodium Tablets<br/><b>Sponsor</b>:   Assiut University<br/><b>Completed</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Topical Antibacterial Agents for Prevention of COVID-19</strong> - <b>Conditions</b>:   COVID-19;   SARS-CoV2 Infection<br/><b>Interventions</b>:   Drug: Neosporin;   Other: Vaseline<br/><b>Sponsors</b>:   Yale University;   Bill and Melinda Gates Foundation<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">**NanoMn®_COVID-19 A Prospective, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blind Trial to Evaluate the Clinical Efficacy of NanoManganese® on Top of Standard of Care, in Adult Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19)** - <b>Condition</b>:   COVID-19 Pandemic<br/><b>Interventions</b>:   Drug: Placebo;   Drug: Experimental drug<br/><b>Sponsor</b>:   Medesis Pharma SA<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Plasma Exchange Therapy for Post- COVID-19 Condition: A Pilot, Randomized Double-Blind Study</strong> - <b>Condition</b>:   Post-COVID19 Condition<br/><b>Interventions</b>:   Combination Product: Plasma Exchange Procedure;   Other: Sham Plasma Exchange Procedure<br/><b>Sponsors</b>:   Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia;   IrsiCaixa;   Banc de Sang i Teixits<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Evaluation of Effectiveness of Proprietary Rehabilitation Program in Patients After COVID-19 Infection</strong> - <b>Conditions</b>:   COVID-19;   Rehabilitation<br/><b>Interventions</b>:   Other: Respiratory training with the use of resistance set on respiratory muscle trainer;   Other: Respiratory training without resistance set on respiratory muscle trainer<br/><b>Sponsor</b>:   Medical University of Bialystok<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Developing an Integrative, Recovery-Based, Post-Acute COVID-19 Syndrome (PACS) Psychotherapeutic Intervention</strong> - <b>Condition</b>:   Post-acute COVID-19 Syndrome<br/><b>Intervention</b>:   Behavioral: PACS Coping and Recovery (PACS-CR) Intervention<br/><b>Sponsor</b>:   VA Office of Research and Development<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Mineralocorticoid Use in COVID-19 Patients</strong> - <b>Conditions</b>:   COVID-19;   ARDS<br/><b>Intervention</b>:   Drug: Fludrocortisone Acetate 0.1 MG<br/><b>Sponsor</b>:   Ain Shams University<br/><b>Completed</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Dose Escalation Phase 1 Study Evaluating the Safety and Pharmacokinetics of an Inhaled COVID-19 Inhibitor Delcetravir in Healthy Subjects</strong> - <b>Condition</b>:   COVID-19<br/><b>Intervention</b>:   Combination Product: Delcetravir dry powder inhaler<br/><b>Sponsor</b>:   Esfam Biotech Pty Ltd<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Biological: Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector);   Biological: Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation;   Biological: mRNA-based COVID-19 vaccine<br/><b>Sponsor</b>:   CanSino Biologics Inc.<br/><b>Not yet recruiting</b></p></li>
</ul>
<h1 data-aos="fade-right" id="from-pubmed">From PubMed</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>In vitro evolution predicts emerging SARS-CoV-2 mutations with high affinity for ACE2 and cross-species binding</strong> - Emerging SARS-CoV-2 variants are creating major challenges in the ongoing COVID-19 pandemic. Being able to predict mutations that could arise in SARS-CoV-2 leading to increased transmissibility or immune evasion would be extremely valuable in development of broad-acting therapeutics and vaccines, and prioritising viral monitoring and containment. Here we use in vitro evolution to seek mutations in SARS-CoV-2 receptor binding domain (RBD) that would substantially increase binding to ACE2. We find…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Drug repurposing based on a quantum-inspired method versus classical fingerprinting uncovers potential antivirals against SARS-CoV-2</strong> - The COVID-19 pandemic has accelerated the need to identify new antiviral therapeutics at pace, including through drug repurposing. We employed a Quadratic Unbounded Binary Optimization (QUBO) model, to search for compounds similar to Remdesivir, the first antiviral against SARS-CoV-2 approved for human use, using a quantum-inspired device. We modelled Remdesivir and compounds present in the DrugBank database as graphs, established the optimal parameters in our algorithm and resolved the Maximum…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Cap-independent translation and a precisely located RNA sequence enable SARS-CoV-2 to control host translation and escape anti-viral response</strong> - Translation of SARS-CoV-2-encoded mRNAs by the host ribosomes is essential for its propagation. Following infection, the early expressed viral protein NSP1 binds the ribosome, represses translation, and induces mRNA degradation, while the host elicits an anti-viral response. The mechanisms enabling viral mRNAs to escape this multifaceted repression remain obscure. Here we show that expression of NSP1 leads to destabilization of multi-exon cellular mRNAs, while intron-less transcripts, such as…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Iron and iron-related proteins in COVID-19</strong> - COVID-19 can cause detrimental effects on health. Vaccines have helped in reducing disease severity and transmission but their long-term effects on health and effectiveness against future viral variants remain unknown. COVID-19 pathogenesis involves alteration in iron homeostasis. Thus, a contextual understanding of iron-related parameters would be very valuable for disease prognosis and therapeutics.Accordingly, we reviewed the status of iron and iron-related proteins in COVID-19….</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies</strong> - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the causative agent of the pandemic COVID-19 disease that affects human respiratory function. Despite the scientific progression made in the development of the vaccine, there is an urgent need for the discovery of antiviral drugs for better performance at different stages of SARS-CoV-2 reproduction. The main protease (Mpro or 3CLpro) plays a pivotal role in the life cycle of the virus, making it an attractive target for the…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Variations of SARS-CoV-2 in the Iranian population and candidate putative drug-like compounds to inhibit the mutated proteins</strong> - The first cases of the novel coronavirus, SARS-CoV-2, were detected in December 2019 in Wuhan, China. Nucleotide substitutions and mutations in the SARS-CoV-2 sequence can result in the evolution of the virus and its rapid spread across the world. Therefore, understanding genetic variants of SARS-CoV-2 and targeting the conserved elements responsible for viral replication have great benefits for detecting its infection sources and diagnosing and treating COVID-19. In this study, we used the…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Synthesis, spectral characterization, crystal structure and computational investigation of 2-formyl-6-methoxy-3-carbethoxy quinoline as potential SARS-CoV inhibitor</strong> - The recent COVID-19 outbreak caused by the novel coronavirus SARS-CoV-2 has an immense impact on global health and economy. Although vaccines are being used, urgent need of drugs based on natural products with high efficacy and safety is a pressing priority. Quinoline alkaloids are well known for their therapeutic action against malaria; initially, it was tried against Coronaviruses. It is a basic vital scaffold to design drugs with required biological and pharmacological activities. In this…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Anti-Histamine Azelastine, Identified by Computational Drug Repurposing, Inhibits Infection by Major Variants of SARS-CoV-2 in Cell Cultures and Reconstituted Human Nasal Tissue</strong> - Background and purpose: The COVID-19 pandemic continues to pose challenges, especially with the emergence of new SARS-CoV-2 variants that are associated with higher infectivity and/or compromised protection afforded by the current vaccines. There is a high demand for additional preventive and therapeutic strategies effective against this changing virus. Repurposing of approved or clinically tested drugs can provide an immediate solution. Experimental Approach: We applied a novel computational…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Discovery of TCMs and derivatives against the main protease of SARS-CoV-2 via high throughput screening, ADMET analysis, and inhibition assay in vitro</strong> - The rapidly evolving Coronavirus Disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide with thousands of deaths and infected cases. For the identification of effective treatments against this disease, the main protease (M^(pro)) of SARS‑CoV‑2 was found to be an attractive drug target, as it played a central role in viral replication and transcription. Here, we report the results of high-throughput molecular docking with…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Carlina oxide inhibits the interaction of SARS-CoV-2 S glycoprotein with angiotensin-converting enzyme 2</strong> - Carlina acaulis plant is a potential target for the industrial production of phytochemicals that display applicability in pharmacy and medicine. The dry roots of C. acaulis contain up to 2 % of essential oil, the main component (up to 99 %) of which is carlina oxide [2-(3-phenylprop-1-ynyl)furan]. This compound shows multidirectional biological activity, including antibacterial and antifungal properties. Here, we evaluated the capacity of carlina oxide to inhibit the interaction between…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Protein-protein conjugation enhances immunogenicity of SARS-CoV-2 Receptor Binding Domain (RBD) vaccines</strong> - Several effective SARS-CoV-2 vaccines have been developed using different technologies. Although these vaccines target the isolates collected early in the pandemic, many have protected against serious illness from newer variants. Nevertheless, efficacy has diminished against successive variants and the need for effective and affordable vaccines persists especially in the developing world. Here, we adapted our protein-protein conjugate vaccine technology to generate a vaccine based on receptor…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Conserved 3’ UTR of Severe Acute Respiratory Syndrome Coronavirus 2: Potential Therapeutic Targets</strong> - Our previous paper showed that microRNAs (miRNAs) present within human placental or mesenchymal stem cell-derived extracellular vesicles (EVs) directly interacted with the RNA genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), inhibiting viral replication. In this paper, we analyzed whether these miRNAs could exert antiviral activity against other variants of SARS-CoV-2. We downloaded compete SARS-CoV-2 genome data submitted to the National Center for Biotechnology…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Paxlovid: Mechanism of Action, Synthesis, and <em>In Silico</em> Study</strong> - In this work, the discovery and description of PF-07321332, a major bioavailable oral SARS-CoV-2 protease inhibitor with in vitro human coronavirus antiviral activity, and excellent selection of off-target and in vivo immune profiles are reported. Various drugs and novel compound candidates for the treatment of the COVID-19 pandemic have been developed. PF-07321332 (or nirmatrelvir) is a new oral antiviral drug developed by Pfizer. In response to the pandemic, Pfizer has developed the COVID…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The SARS-CoV-2 main protease (M<sup>pro</sup>): Structure, function, and emerging therapies for COVID-19</strong> - The main proteases (M^(pro)), also termed 3-chymotrypsin-like proteases (3CL^(pro)), are a class of highly conserved cysteine hydrolases in β-coronaviruses. Increasing evidence has demonstrated that 3CL^(pro)s play an indispensable role in viral replication and have been recognized as key targets for preventing and treating coronavirus-caused infectious diseases, including COVID-19. This review is focused on the structural features and biological function of the severe acute respiratory syndrome…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Lopinavir-menthol co-crystals for enhanced dissolution rate and intestinal absorption</strong> - Lopinavir is an antiretroviral, antiparasitic agent and recently utilized in treatment of COVID-19. Unfortunately, lopinavir exhibited poor oral bioavailability due to poor dissolution, extensive pre-systemic metabolism, and significant P-glycoprotein intestinal efflux. Accordingly, the aim was to enhance dissolution rate and intestinal absorption of lopinavir. This employed co-processing with menthol which is believed to modify crystalline structures and inhibit intestinal efflux. Lopinavir was…</p></li>
</ul>
<h1 data-aos="fade-right" id="from-patent-search">From Patent Search</h1>
<script>AOS.init();</script></body></html>

513
archive-daily-dose/19 July, 2022.html Normal file
View File

@ -0,0 +1,513 @@
<!DOCTYPE html>
<html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
<meta charset="utf-8"/>
<meta content="pandoc" name="generator"/>
<meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
<title>19 July, 2022</title>
<style type="text/css">
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
span.underline{text-decoration: underline;}
div.column{display: inline-block; vertical-align: top; width: 50%;}
</style>
<title>Daily-Dose</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><style>*{overflow-x:hidden;}</style><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
<body>
<h1 data-aos="fade-down" id="daily-dose">Daily-Dose</h1>
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
<ul>
<li><a href="#from-new-yorker">From New Yorker</a></li>
<li><a href="#from-vox">From Vox</a></li>
<li><a href="#from-the-hindu-sports">From The Hindu: Sports</a></li>
<li><a href="#from-the-hindu-national-news">From The Hindu: National News</a></li>
<li><a href="#from-bbc-europe">From BBC: Europe</a></li>
<li><a href="#from-ars-technica">From Ars Technica</a></li>
<li><a href="#from-jokes-subreddit">From Jokes Subreddit</a></li>
</ul>
<h1 data-aos="fade-right" id="from-new-yorker">From New Yorker</h1>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Is Abortion Sacred?</strong> - Abortion is often talked about as a grave act. But bringing a new life into the world can feel like the decision that more clearly risks being a moral mistake. - <a href="https://www.newyorker.com/culture/essay/is-abortion-sacred">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Psychologists Treating Rape Victims in Ukraine</strong> - A grassroots effort is offering mental-health care to Ukrainians who’ve faced sexual violence at the hands of the Russian invasion force. - <a href="https://www.newyorker.com/news/dispatch/the-psychologists-treating-rape-victims-in-ukraine">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Herschel Walker’s Deficits Are Not the Only Cause for Concern</strong> - His Senate candidacy is a clear example of the warping effect that Donald Trump has had on the Republican Party nationally. - <a href="https://www.newyorker.com/magazine/2022/07/25/herschel-walkers-deficits-are-not-the-only-cause-for-concern">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>​​Another Likely Effect of the Roe Reversal: Higher Health-Care Costs</strong> - Abortion bans could lead to more high-risk pregnancies, which could raise the price of providing health care to women. - <a href="https://www.newyorker.com/business/currency/another-likely-effect-of-the-roe-reversal-higher-health-care-costs">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The True Costs of Inflation in Small-Town Texas</strong> - When R-BBQ had to cut its hours and reduce its portions, the effects rippled through the community. - <a href="https://www.newyorker.com/news/letter-from-the-southwest/the-true-costs-of-inflation-in-small-town-texas">link</a></p></li>
</ul>
<h1 data-aos="fade-right" id="from-vox">From Vox</h1>
<ul>
<li><strong>The case for caring less</strong> -
<figure>
<img alt="" src="https://cdn.vox-cdn.com/thumbor/8bXE8J2FnBUw9WIncAXxJuVH-_M=/375x0:2626x1688/1310x983/cdn.vox-cdn.com/uploads/chorus_image/image/71151054/STORY_5_SET_2.0.png"/>
<figcaption>
Shanée Benjamin for Vox
</figcaption>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
“Don’t sweat the small stuff” is actually great advice.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="ptCYJt">
To say that our plates are full would be an understatement. The reality of contemporary living requires our attention and efforts be divided between demanding jobs, essential familial caregiving, replenishing social gatherings, and fulfilling political and community engagements — not to mention any hobbies or creative endeavors. According to <a href="https://www.pewresearch.org/fact-tank/2020/02/05/how-americans-feel-about-the-satisfactions-and-stresses-of-modern-life/">Pew Research Center surveys</a>, 60 percent of adults said they were sometimes too busy to enjoy life. Busy-ness, unsurprisingly, intensifies once you have kids: 74 percent of parents with children under the age of 18 reported being too busy to enjoy life.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="RTiGn8">
There are a number of reasons people pack their schedules. <a href="https://www.nytimes.com/2019/01/26/business/against-hustle-culture-rise-and-grind-tgim.html">Hustle culture</a> has normalized always-on, blind ambition; society still <a href="https://www.pewresearch.org/fact-tank/2015/03/10/women-still-bear-heavier-load-than-men-balancing-work-family/">expects women to balance the pressures</a> of work and home life; <a href="https://www.npr.org/2020/09/15/913207918/how-to-say-no-for-the-people-pleaser-who-always-says-yes">people pleasers</a> have difficulty saying no. Existential fears of climate change, political turmoil, and economic strain perhaps weigh less heavily when you’re distracted by a never-ending to-do list.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="HyDl8i">
“We’re socialized,” says licensed marriage and family therapist <a href="https://www.monalmft.com/">Mona Eshaiker</a>, “to care and to provide and to help. If we do it without boundaries and without limits, we’re going to be burnt out and then we’re not doing anybody any favors.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="2Bf5dD">
The myth of perfectionism keeps many in a cycle of feeding into external pressures: the illusion of “having it all,” gleaning self-worth from the validation of others. Of course, it is worthy and noble to be passionate about people and causes you care about. It’s also easy to fall into the trap of attempting too much in the pursuit of trying to have it all.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="hMb8MP">
Instead of being everything to everyone and everything all the time, what would life look like if you cared a little less? “What if,” says <a href="https://academics.uscb.edu/humanities-social-sciences/sociology/faculty/deborah-cohan.html">Deborah J. Cohan</a>, professor of sociology at University of South Carolina Beaufort and author of <a href="https://www.rutgersuniversitypress.org/welcome-to-wherever-we-are/9781978808928"><em>Welcome to Wherever We Are: A Memoir of Family, Caregiving, and Redemption</em></a>, “we aim for good enough?”
</p>
<h3 id="9X7vTK">
Manage your personal expectations
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="1SuTgG">
Much of our desire to take on extra tasks and responsibilities comes from a sense of obligation to others, experts agree, but even that can be self-directed. “Seventy-five percent of the time, the guilt is coming from inside the house,” says <a href="https://sarahknight.com/">Sarah Knight,</a> author of a series of “No Fucks Given” guides, including <a href="https://sarahknight.com/lcm/"><em>The Life-Changing Magic of Not Giving a Fuck</em></a><em> </em>and <a href="https://sarahknight.com/gyst/"><em>Get Your Shit Together</em></a>. “You are making it up in your own head.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="9IqkoK">
No one’s expectations of you are as high as your self-imposed expectations. If you feel guilty about bringing store-bought pasta salad to a barbecue instead of a homemade dish, the only person who is going to shame you for that is yourself. While turning down additional responsibilities at work because your plate is already full can feel like you’re dropping the ball, most likely the asker will quickly find a volunteer who is more than eager to take on the extra project. “Nobody’s mad,” Eshaiker says. “People don’t want us to feel pressured, either, or stressed.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="ruX6T1">
Before making a decision about whether to care a little less or to turn down a favor that’s asked of you, Knight says to ask yourself whether saying no would have a negative effect or comes from a mean-spirited place. “RSVPing no to a party is not an objectively bad thing,” she says. “Saying yes and then canceling at the last minute — not because you legitimately got food poisoning but because you never really wanted to go … that’s something you can feel guilty about. Don’t do that.”
</p>
<h3 id="toG69p">
Find your priorities
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="5BVpyd">
Caring less doesn’t mean negligence. To care less about inconsequential matters, you need to zero in on what is worth caring for. Consider taking stock of to-do list items and obligations and asking if these responsibilities make your day feel more spacious or more confined, Cohan suggests. Does it nourish your sense of creativity? Is it the best use of your time and talent? Does it make you feel exhausted? Do you want to spend your time and energy on this?
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="JRSXmL">
Eshaiker says to ask yourself, “Why do I care?” about various aspects of life. “Is this something that is aligned with my values?” she says. “Is this something that I believe is helpful for myself and for humanity?” If you feel compelled to care about something out of fear or wanting to be accepted by others, it may not be worth placing emphasis on it.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="RPASoR">
Of course, there are nonnegotiable obligations — the basic functions of your job, caring for children, paying bills — which may not be life-affirming but require attention nonetheless. Once you define these true commitments, you can “divorce yourself from the concept of ‘I have to do it,’” Knight says, when it comes to other tasks you thought essential, like waking up at 5 am to do laundry when doing it after work will suffice.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="bwFjml">
When Knight quit her job as a book editor in 2015, she realized what Marie Kondo advocated for in terms of physical organization, Knight was doing to her brain: eliminating the habits and people that no longer sparked joy. Think about the instances you really didn’t enjoy or that made your life more difficult — such as attending a casual friend’s bachelor party when you really wanted to catch up on reading instead. When similar opportunities arise, you can confidently turn down things you know won’t serve you, Cohan says.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="3Qtmue">
Just because you excel at something — be it creating detailed spreadsheets or making complicated desserts for dinner parties — doesn’t mean you have to agree to it every time you’re asked or volunteer to do it to impress others. “Even though I know I can make the really great, complicated cake — I’ve made them, I’m good at it,” Cohan says. “But it doesn’t mean I have to do it because maybe it’s not the best use of my Saturday.”
</p>
<h3 id="6STy4v">
Zoom out
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="2PquUP">
In the thick of the daily grind, minute conflicts can often get blown out of proportion: Your kid didn’t do the dishes when you asked, you were 10 minutes late to a doctor’s appointment, a friend forgot she was supposed to bring snacks to game night. People are quick to ascribe meaning to these ordinary events — jumping to conclusions and thinking a friend is inconsiderate, say, by not answering your phone call in the middle of a workday. If you pause and take a step back, none of these things actually<em> </em>have a profound bearing on your life, Eshaiker says. Say you find yourself constantly wrapped up in drama — consider asking yourself why you’re stimulated by the excitement of conflict or which big life decisions you’re trying to distract from. “Sometimes not reacting is the best thing to do,” she says.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Uh6uPD">
The same thing goes for work. Many people’s value and self-worth is intrinsically tied to their jobs. But if you zoom out and consider who you are outside of your job, you may realize other areas of life where you might be lacking, like spending quality time with family or practicing art or music — parts of life you decided you want to prioritize.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="EW0OYT">
When you’re constantly stressed and in a fight-or-flight state of mind, finding this perspective is difficult, Eshaiker continues. Every minor issue feels like an urgent fire needing to be extinguished. Instead of making mountains out of molehills, Eshaiker suggests getting to the root of why you’re negatively fixated on the outfit your partner decided to wear to a wedding, for example. “Is it because I want my partner to present well in public because then I want to get approval from others?” she says. “But that has nothing to do with my ultimate values and my goals. Again, you’re just giving up your power to other people if it’s about external validation in some way.” Relinquishing the perceived influence onlookers have over your life frees up space for you to care about things that actually matter.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="iQ8QFd">
In order to get to a place where you’re able to look at the bigger picture, Eshaiker says you need to prioritize rest and centering yourself, which looks different for everyone: meditation, taking a walk, no email before bed.
</p>
<h3 id="mTTV1N">
Set boundaries
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="FyxU37">
Once you’ve defined what is and isn’t worth your time, you’ve got to set, and express, boundaries. Boundary-setting can seem like an amorphous buzzword, but it isn’t as simple as learning how to say no. According to Knight, boundary-setting is outlining what you need and what is important to you and protecting those desires. This can be as simple as writing a list of things that make you happy (reading, going to the gym, cooking, a life with minimal stress), allow you to earn a living (your job), and other areas of importance (friends, family, getting a good night’s sleep).
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Lecc5G">
Then ask yourself what you need to do to protect these things. Maybe you decline invites to weeknight social activities in order to prioritize good sleep. Perhaps you need to spend less time with a friend who invites conflict.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="JNUdOn">
“If they really sit down and think about it for five minutes, they’re gonna realize the biggest, unwanted drain on their time, energy, and money,” Knight says. “It could be a relationship in their life — it could be a parent, it could be a friend, someone they’re dating — and that the boundary that you need to set to preserve your time, energy, money, sanity, mental health, is to basically fence that person outside of all of that.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="tkcK7n">
Another way to set boundaries, Knight says, is to ask yourself, “What’s wrong with my life?” and then to identify why. For example, you might feel depleted after hanging out with a certain friend. Why? Are you giving more than they’re willing to reciprocate? Do you no longer have much in common? “It all comes down to identifying what you want, the need, what’s important to you, and then what you have to do to protect those things,” Knight says.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="8kQ98B">
Time is finite and shouldn’t be dictated by others or how you believe others to perceive you. If caring a little less means not immediately volunteering to lead every new initiative at work or skipping a few PTA meetings, you’re saving time and energy for the things that matter.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="nbNaS5">
“It’s like trimming the fat,” Cohan says, “off of a day or a week.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="XDFlp7">
<a href="http://www.vox.com/even-better"><em>Even Better</em></a><em> is here to offer deeply sourced, actionable advice for helping you live a better life. Do you have a question on money and work; friends, family, and community; or personal growth and health? Send us your question by filling out this </em><a href="https://docs.google.com/forms/d/e/1FAIpQLSfiStGSlsWDBmglim7Dh1Y9Hy386rkeKGpfwF6BCjmgnZdqfQ/viewform"><em>form</em></a><em>. We might turn it into a story.</em>
</p></li>
<li><strong>9 questions about the January 6 committee, answered</strong> -
<figure>
<img alt="" src="https://cdn.vox-cdn.com/thumbor/tRzAXyCwassmEAliRZMfm6yQ-Bg=/554x0:4983x3322/1310x983/cdn.vox-cdn.com/uploads/chorus_image/image/71150857/GettyImages_1241440220.0.jpg"/>
<figcaption>
Former President Donald Trump is displayed on a screen during the fourth hearing of the January 6 investigation in the Cannon House Office Building in Washington, DC, on June 21. | Al Drago/Getty Images
</figcaption>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
What is the point of the January 6 committee? Will Trump face any consequences based on what it finds?
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="THuFqI">
The House January 6 committee’s primetime hearing Thursday will represent the culmination of the <a href="https://www.vox.com/2022/6/9/23161364/january-6-committee-capitol-congress-public-hearings">series of eight hearings</a> that stretched across the better part of the summer. Rep. Jamie Raskin (D-MD) <a href="https://www.vox.com/23205667/donald-trump-witness-tampering-january-6-hearing-takeaways">said last week</a> that this week’s hearing would “be a profound moment of reckoning for America.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="L9nZ43">
It may not reach quite that level — it’s still just a congressional hearing — but it is expected to shed new light on former President Donald Trump’s actions on January 6, 2021, while the mob attacked the Capitol.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="2j6lN0">
Although the committee has been getting ample coverage on cable news since the public hearings began in early June, this is likely to be the most watched and talked about of its hearings.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Ak6qzP">
Here are answers to some of the biggest questions about the January 6 committee, so you can make sense of what is revealed Thursday and what all this is actually leading to.
</p>
<h3 id="PG51vh">
<ol type="1">
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">What is the point of the January 6 committee?
</li></ol></h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="vGRWyc">
Although the events of January 6 were amply covered at the time and have since been the topic of books, documentaries, and a presidential impeachment trial, there have been countless questions about the attack on the US Capitol left unanswered. Was it planned or organized in any way? And, if so, by whom? What was Donald Trump doing while his supporters ransacked the Capitol? And how did it fit into Trump’s months-long effort to overturn the 2020 presidential election and keep himself in office? These questions were left lingering even after <a href="https://www.vox.com/22223972/trump-impeached-house-senate-trial-former-president">Trump was impeached</a> for inciting the attack, and have never fully been answered.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="PLjvaL">
The January 6 committee was created by Congress to investigate the circumstances around the attack on the Capitol, <a href="https://www.congress.gov/bill/117th-congress/house-resolution/503/text">to recommend</a> “changes in law, policy, procedures, rules, or regulations” to prevent future acts of violence, and “to strengthen the security and resilience of the United States and American democratic institutions.” It was created with <a href="https://clerk.house.gov/Votes/2021197">a near party-line vote</a> in June 2021, with only the two Republicans who ended up on the committee, Reps. Liz Cheney (R-WY) and Adam Kinzinger (R-IL), voting for it.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="jWZGCS">
The final work product of the committee is not the televised hearings, or punishing anyone for wrongdoing it uncovers, but instead a formal report to Congress. That’s expected to be issued in the fall; it is anticipated to explain how the attack on the Capitol happened and outline future steps to prevent similar occurrences in the future.
</p>
<h3 id="TH6tjc">
<ol start="2" type="1">
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">So what has it been doing so far?
</li></ol></h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="uEMfo9">
With its broad mandate, the committee has interviewed over 1,000 witnesses and focused intensively on the actions of Donald Trump in the weeks and months before the pro-Trump mob stormed the Capitol on January 6.
</p>
<figure class="e-image">
<img alt=" " src="https://cdn.vox-cdn.com/thumbor/vB3Oxu_Ii50P2RKVkyTpyUUtpMw=/800x0/filters:no_upscale()/cdn.vox-cdn.com/uploads/chorus_asset/file/23885158/AP22194583988791.jpg"/> <cite>Julio Cortez/AP</cite>
<figcaption>
Insurrectionists loyal to President Donald Trump try to break through a police barrier on January 6, 2021, at the US Capitol in Washington, DC.
</figcaption>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="bgVZRN">
The committee worked for months before it started making its case to the public, though much of what it found out behind closed doors was revealed in press reports. Those leaks of committee findings included reports about a <a href="https://www.politico.com/f/?id=0000017e-920d-d65f-a77e-fbad182f0000">draft executive order</a> prepared for Trump to have the military seize voting machines, <a href="https://www.cnn.com/2022/04/15/politics/mike-lee-chip-roy-text-messages-jan-6-mark-meadows-overturn-election/index.html">text messages</a> sent by former White House chief of staff Mark Meadows urging members of Congress to act to overturn the election, and <a href="https://www.washingtonpost.com/national-security/2022/06/15/ginni-thomas-john-eastman-emails/">correspondence</a> between Trump adviser John Eastman and Ginni Thomas, the wife of Supreme Court Justice Clarence Thomas.
</p>
<aside id="eQhYXp">
<div>
</div>
</aside>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="wljjm3">
Since June, the committee has <a href="https://www.vox.com/2022/6/9/23161364/january-6-committee-capitol-congress-public-hearings">held seven public hearings</a> geared at assembling a cohesive, comprehensive story of the organized, multi-pronged effort to overturn the result of the 2020 presidential election, with Trump at its center. So far, the hearings have focused on aspects of that plan, like:
</p>
<ul>
<li id="n3D3qq">
Attempts by Trump to <a href="https://www.vox.com/2022/6/21/23177237/january-6-hearings-bowers-raffensperger">pressure Republican state officials</a> to try to reverse Joe Biden’s wins in several swing states.
</li>
<li id="RGIs2G">
The effort to push Vice President Mike Pence into unilaterally and unconstitutionally <a href="https://www.vox.com/2022/6/16/23171707/january-6-committee-hearing-pence-trump-day-three">throwing out electoral votes</a> in his role presiding over the formal certification of the 2020 election.
</li>
<li id="V27wZn">
The effort to force <a href="https://www.vox.com/2022/6/23/23180854/january-6-hearings-justice-department-trump-coup">Justice Department officials</a> to take legal actions seeking a different election result in court.
</li>
<li id="1v85wP">
What happened when <a href="https://www.vox.com/23205667/donald-trump-witness-tampering-january-6-hearing-takeaways">all of those failed</a>, and Trump then focused on his rally on January 6 to try to bring his supporters to Washington, DC, in a last-ditch effort to hold on to power.
</li>
</ul>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="ZeOvUM">
Unlike other congressional hearings that feature lengthy opening statements and ample speechifying, these have run more like scripted television programs. The committee has even used a former television news executive as a consultant, and that shows in the polished production: It weaves together clips of videotaped depositions and occasionally alternates those with live questioning of the witnesses before the committee.
</p>
<h3 id="IKZRHg">
<ol start="3" type="1">
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Could the committee’s work result in actual consequences for Trump or anyone else?
</li></ol></h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="eu8MEH">
Yes, it could.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="YOcSx8">
The committee doesn’t have the authority to punish anyone. Much has been made about whether it might issue criminal referrals to ask the Justice Department to indict Trump or others involved in efforts to overturn the election. These, however, don’t carry any real legal weight. One could tag Attorney General Merrick Garland on a tweet asking him to indict Trump and it would have much the same independent effect.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="7hQcDJ">
But the resources the committee has put toward investigating January 6 have produced evidence that <a href="https://www.nytimes.com/2022/07/13/us/politics/jan-6-committee-evidence-justice-department.html">could eventually be shared</a> with the Justice Department to buttress its investigation.
</p>
<figure class="e-image">
<img alt=" " src="https://cdn.vox-cdn.com/thumbor/ark31KjaqjQr1JiS1jwdGTvMEmY=/800x0/filters:no_upscale()/cdn.vox-cdn.com/uploads/chorus_asset/file/23885105/GettyImages_1236302381.jpg"/> <cite>Andy Cross/MediaNews Group/The Denver Post via Getty Images</cite>
<figcaption>
Former Trump attorney John Eastman speaks at a news conference in Boulder, Colorado, on April 29, 2021, about his plans to sue University of Colorado Boulder. Eastman, a visiting professor of conservative thought and policy, was relieved of his duties at the university for speaking at Trump’s January 6 rally.
</figcaption>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="g7qET2">
Perhaps the most meaningful legal impact of the committee’s investigation so far came in <a href="https://storage.courtlistener.com/recap/gov.uscourts.cacd.841840/gov.uscourts.cacd.841840.260.0.pdf">a 44-page ruling</a> from David Carter, a federal judge in California. In the ruling, Carter held that documents the committee subpoenaed from John Eastman, an outside Trump lawyer, were not protected by attorney-client privilege. This was because, he wrote, Eastman and Trump were acting as criminal co-conspirators trying to mount “a coup in search of a legal theory.” In stark language, Carter wrote, “the Court finds it more likely than not that President Trump corruptly attempted to obstruct the Joint Session of Congress on January 6, 2021” and “that President Trump and Dr. Eastman dishonestly conspired to obstruct the Joint Session of Congress on January 6, 2021.”
</p>
<aside id="e9P4cV">
<div>
</div>
</aside>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="7gfWop">
This doesn’t mean Trump will get prosecuted. After all, the decision whether to charge Trump, Eastman, or anyone else with a crime doesn’t rest with a federal judge but with prosecutors. But it does come freighted with significance that a nonpartisan actor issued a formal legal ruling saying it is more likely than not that a sitting president committed a crime.
</p>
<h3 id="knrybU">
<ol start="4" type="1">
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">What does this have to do with the Justice Department investigation?
</li></ol></h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="P03Tph">
You could view the committee’s investigation of January 6 and the DOJ’s investigations as two trains running on parallel tracks, investigating the same thing in different ways. The committee has moved from closed-door interviews to televised hearings while the Justice Department has been steadily prosecuting those who entered the Capitol grounds on January 6. <a href="https://www.justice.gov/usao-dc/18-months-jan-6-attack-capitol">As of early July</a>, 855 people had been arrested across the country. About 330 have pleaded guilty to various charges, while 10 have gone to trial and been found guilty.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="sJ7Ojk">
Recently, however, the DOJ has stepped up its efforts, raiding and seizing electronic devices of figures like Eastman as well as of those who were involved in schemes around the electoral vote-counting process. It is unclear exactly what connection this new push by the DOJ has to the committee’s work.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="LGMJN2">
Eventually, the two tracks will converge once the committee issues its report and turns over its investigative material to the Department of Justice. The question then is simply what Garland will do with the evidence the committee has gathered as well as that gathered by his own prosecutors.
</p>
<aside id="BfoZ4a">
<div>
</div>
</aside>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="jcbVjI">
The final decision to prosecute Trump and his associates will fall into Garland’s lap. The attorney general <a href="https://www.latimes.com/politics/story/2022-07-10/prosecute-trump-merrick-garland-is-investigating-aggressively-but-prosecuting-cautiously">will have to weigh</a> not only the strength of evidence and the likelihood that a jury would convict, but also whether to set the precedent of indicting a former president, which would be a first in American history.
</p>
<h3 id="uZA8RT">
<ol start="5" type="1">
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Who are the participants I need to know about?
</li></ol></h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="xZqhTD">
The two bold-faced names running the committee are its chair Rep. Bennie Thompson (D-MS) and its vice chair, Liz Cheney. These are the only two members of the committee who speak at every hearing. Cheney has often played an active role in hearings; her opening and closing statements provide a road map for what the committee intends to do and hints of new revelations to come.
</p>
<figure class="e-image">
<img alt=" " src="https://cdn.vox-cdn.com/thumbor/NHKnNm_CV-ACOjWj7znJER0V6cE=/800x0/filters:no_upscale()/cdn.vox-cdn.com/uploads/chorus_asset/file/23885089/AP22179614785896.jpg"/> <cite>Jacquelyn Martin/AP</cite>
<figcaption>
Cassidy Hutchinson, former aide to Trump White House chief of staff Mark Meadows, prepares to testify before the January 6 committee on June 28.
</figcaption>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="H7ypno">
The other person who has come to national prominence through the hearings is <a href="https://www.vox.com/2022/6/28/23186748/cassidy-hutchinson-january-6-hearing-committee">Cassidy Hutchinson</a>, a now-26-year-old former White House aide. The committee devoted a hearing in late June solely to Hutchinson, a previously obscure figure, which featured testimony about Trump’s desire to go to the Capitol on January 6 and about members of Congress who allegedly sought presidential pardons for their own efforts to overturn the 2020 election.
</p>
<aside id="2hJVIJ">
<div>
</div>
</aside>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="2xTiJM">
So far, Hutchinson has been the only White House aide to testify in person before the committee and willingly provide revelatory testimony. There have been plenty of other Trump White House aides who have appeared via their videotaped depositions and made memorable contributions, including White House lawyer Eric Herschmann and former Attorney General Bill Barr. Most recently, White House counsel <a href="https://www.vox.com/2022/7/8/23200686/who-is-pat-cipollone-trump-lawyer-testifying">Pat Cipollone</a> finally testified before the committee, and clips of his deposition are expected to feature prominently during Thursday’s hearing. Others in Trump’s orbit have appeared in person for hearings, including former acting Attorney General Jeffrey Rosen and Greg Jacob, the counsel for Vice President Mike Pence.
</p>
<h3 id="RLO9Lw">
<ol start="6" type="1">
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">And what’s going on with people like Steve Bannon who weren’t cooperating?
</li></ol></h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="zFq2sg">
While many big names in Trumpworld have cooperated and the committee has played clips of depositions from top Trump allies including his daughter Ivanka Trump, his son-in-law Jared Kushner, and his former campaign manager Bill Stepien, several well-known figures in Trump’s orbit have refused to do so.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Aji3dI">
The most well-known is <a href="https://www.vox.com/2022/7/17/23217452/steve-bannon-january-6-trump-propaganda-election">Steve Bannon</a>, the former top White House strategist who has since been an outside adviser to Trump. Bannon initially refused to cooperate with the committee at all. It then cited him for contempt of Congress, and the House voted to recommend that the Justice Department prosecute him for his refusal to cooperate. Bannon turned himself in last November, and, after months of legal wrangling, his <a href="https://apnews.com/article/steve-bannon-trial-jury-selection-0cde38cf0cd8141441968b470be2acbd">trial is set to begin</a> on Monday. The former Trump adviser captured attention in the past week with a last-minute offer to testify before the committee that was <a href="https://storage.courtlistener.com/recap/gov.uscourts.dcd.237438/gov.uscourts.dcd.237438.105.0_1.pdf">dismissed by the Justice Department</a> as “not a genuine effort to meet his obligations but a last-ditch attempt to avoid accountability.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="8P6UeS">
The committee has referred three others for contempt of Congress after votes in the House. The Department of Justice <a href="https://www.politico.com/news/2022/06/03/doj-declines-to-charge-meadows-scavino-with-contempt-of-congress-for-defying-jan-6-committee-00037230">declined to move forward</a> with prosecutions of former White House chief of staff Mark Meadows and Trump adviser Dan Scavino but has charged Trump trade adviser <a href="https://www.washingtonpost.com/national-security/2022/06/17/peter-navarro-not-guilty-contempt/">Peter Navarro</a> with contempt.
</p>
<figure class="e-image">
<img alt=" " src="https://cdn.vox-cdn.com/thumbor/_WCeuLQeyg9JNRcFLWaTYeDnFMg=/800x0/filters:no_upscale()/cdn.vox-cdn.com/uploads/chorus_asset/file/23885078/GettyImages_1403487311.jpg"/> <cite>Chip Somodevilla/Getty Images</cite>
<figcaption>
Former Trump White House adviser Peter Navarro, left, talks to reporters with his new attorney John Rowley after Navarro was arraigned at the Prettyman US Courthouse in Washington, DC, on June 17 for contempt of Congress.
</figcaption>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Z5Uq2f">
Others appeared before the committee but repeatedly invoked their constitutional right against self-incrimination, including former national security adviser Mike Flynn and former DOJ official <a href="https://www.vox.com/2022/6/23/23179173/jeffrey-clark-doj-january-6">Jeffrey Clark</a>.
</p>
<h3 id="aLUdTB">
<ol start="7" type="1">
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Is this breaking through or having a political impact?
</li></ol></h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="yyCPGy">
The committee is piling up plenty of evidence that Trump knew he lost the 2020 election and then actively conspired to overturn it. Of course, there have been plenty of instances of his misdeeds in the past — dozens of scandals, two impeachments, and an almost infinite number of problematic tweets — yet he’s <a href="https://nymag.com/intelligencer/2022/05/this-will-not-pass-shows-how-trump-was-resurrected.html">weathered those</a> and managed to stay the leader of the Republican Party. It’s hard to imagine that anything will ever shatter Trump’s grip over his MAGA base, and this probably won’t do it.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="XAvpCA">
But there is some evidence that the hearings are <a href="https://www.vox.com/2022/6/29/23188683/hutchinson-trump-republicans-january-6">eroding his general standing</a> within the GOP; reaching some Republicans who were never part of the MAGA wing of the party and reminding them of their horror over the attack on the Capitol.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="tKJlK6">
According to a late June <a href="https://drive.google.com/file/d/1YUL45oZU545gh-hka2DLI9LdjJ-7pEdC/view">poll from CBS/YouGov,</a> a quarter of Trump voters say they are paying some or a lot of attention to the hearings, while over 40 percent of Trump voters think it is very important or somewhat important to find out what happened that day. Further, Trump’s unfavorability <a href="https://projects.fivethirtyeight.com/polls/favorability/donald-trump/">has steadily increased</a> in polling over the past month, while the former president <a href="https://projects.fivethirtyeight.com/polls/president-primary-r/2024/national/">has started to slip</a> under 50 percent in polls for the 2024 Republican nomination.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="x3HS8D">
This is happening while Trump is sounding like a presidential candidate in all but name. Just last week, in <a href="https://nymag.com/intelligencer/article/donald-trump-2024-decision.html">an interview with New York magazine’s Olivia Nuzzi</a>, he implied the only open question is whether he would announce his candidacy before or after the November midterms. While Trump still has a strong core of support within the GOP in a potential primary, he has already lost one presidential election to Biden, and lagged the incumbent in a <a href="https://www.nytimes.com/2022/07/11/us/politics/biden-approval-polling-2024.html">recent New York Times/Siena College poll</a> even though only a third of voters in the same poll approved of Biden’s performance in office. Anything that further dings Trump’s support — even outside the base — is a political liability.
</p>
<h3 id="p6BKdC">
<ol start="8" type="1">
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Is this like anything that has happened before?
</li></ol></h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="S30QTi">
While the January 6 committee has often been compared to Watergate, it has very little in common with the <a href="https://www.npr.org/2022/06/06/1103098399/watergate-committee-hearings-may-be-both-an-inspiration-and-a-hard-act-to-follow">carefully crafted Senate committee</a> that investigated the Watergate break-in, led by conservative Democrat Sam Ervin in 1973, an era when politics was more genteel and most Americans received their news through traditional media outlets.
</p>
<figure class="e-image">
<img alt=" " src="https://cdn.vox-cdn.com/thumbor/wQK5eASWmSuoFYIm6kde0og7YqA=/800x0/filters:no_upscale()/cdn.vox-cdn.com/uploads/chorus_asset/file/23885063/GettyImages_515111652.jpg"/> <cite>Bettmann Archive via Getty Images</cite>
<figcaption>
Senate Watergate committee Chair Sen. Sam Ervin, center, questions John Ehrlichman (back to camera), former presidential aide to Richard Nixon, during the panel’s hearing on July 26, 1973.
</figcaption>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="xKDDGr">
The most unusual aspect of the committee is its non-adversarial nature. After a fight over Republican nominees to the committee led House Minority Leader Kevin McCarthy to refuse to participate, it left the committee without any Trump defenders.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="xNOWwv">
Cheney and Kinzinger, the two Republicans on the committee, <a href="https://www.vox.com/2021/1/13/22228964/house-republicans-trump">both voted to impeach Trump</a>, and that has led to the members working together in a nonpartisan way. The resulting unity of purpose has enabled the hearings to become slick televised productions without any objections, obstruction, or grandstanding. While the decision to refuse to participate was initially made in an effort to delegitimize the committee and make it look like a partisan vehicle after <a href="https://www.vox.com/22588475/kevin-mccarthy-january-6-committee-banks-jordan">House Speaker Nancy Pelosi blocked two of McCarthy’s original nominees from joining the committee</a>, Republicans have since been left regretting the decision. Even Trump <a href="https://www.nbcnews.com/politics/congress/trump-fumes-republicans-ignore-jan-6-panel-rcna34843">has criticized it</a> after the hearings began when he was left without any allies in the room.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="gP6hdc">
The question is what outcomes will result from the committee. The Watergate scandal led to the passage of comprehensive campaign finance laws for the first time in American history (although much of the regime was promptly ruled unconstitutional by the Supreme Court and has been steadily eroded by court decisions since then). While reform of the Electoral Count Act, the arcane 19th-century law that governs the certification of presidential elections, has <a href="https://gen.medium.com/all-your-paranoid-questions-about-the-electoral-college-certification-answered-7b636f6af314">had bipartisan support</a> in the aftermath of the attack on the Capitol, it’s unlikely that there will be more significant legislative proposals. There may still be prosecutions of those involved in the effort to overturn the election, but the question is whether it will reach the scale of Watergate, which led to nearly 50 guilty verdicts.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="kV5rPm">
There also is the specter of Trump or another MAGA candidate winning the White House in 2024 and potentially pardoning anyone prosecuted (including the hundreds already found guilty of breaching the Capitol). Trump has already <a href="https://www.reuters.com/world/us/trump-says-he-would-pardon-jan-6-rioters-if-he-runs-wins-2022-01-30/">expressed at rallies his willingness</a> to do this. There is precedent for this — most of the top government officials wrapped up in the Iran-Contra scandal were pardoned by George H.W. Bush before he left office in 1993.
</p>
<h3 id="HcktWk">
<ol start="9" type="1">
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">What happens next?
</li></ol></h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="CphAWG">
After the primetime hearing on Thursday, there are no immediate plans for more hearings, though the committee <a href="https://www.nbcnews.com/politics/congress/jan-6-committee-wont-rule-hearings-summer-rcna38105">left open the possibility</a> there could be more scheduled if they are warranted. Instead, the committee will continue its investigative process and start to focus more on drafting and writing its report, which is expected to be complete in the early fall. At that point, it will make public whatever recommendations it has and perhaps hold another hearing to present them.
</p>
<figure class="e-image">
<img alt=" " src="https://cdn.vox-cdn.com/thumbor/q5xTNIqYiZNPz6GFXLl-0NDHyqA=/800x0/filters:no_upscale()/cdn.vox-cdn.com/uploads/chorus_asset/file/23885168/GettyImages_1241516460.jpg"/> <cite>Bill O’Leary/Washington Post via Getty Images</cite>
<figcaption>
From left, Rep. Adam Kinzinger, Chairman Bennie Thompson, and Rep. Liz Cheney preside over a June 23 hearing of the House Select Committee to Investigate the January 6th Attack on the United States Capitol.
</figcaption>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="gwLAc9">
The hard deadline for action, though, is <a href="https://www.vox.com/midterm-elections-2022">the midterms</a>. Not only are Democrats expected to lose control of the House, but two of the committee’s members, Kinzinger and Rep. Stephanie Murphy (D-FL), are not running for reelection, while two others face tough races. Cheney is the <a href="https://www.vox.com/2022/6/22/23177243/liz-cheney-wyoming">underdog in her August primary</a> while Rep. <a href="https://nymag.com/intelligencer/2022/04/elaine-luria-on-the-january-6-committees-plans.html">Elaine Luria</a> (D-VA) represents a swing district. The result is that the committee has to accomplish all of its goals by the end of the year.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="SDvaFq">
With Democrats likely to lose the House and Republicans already pledging retribution over the committee’s work, it’s unlikely that anything proposed by the committee would stand a chance of passing the House in 2023.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="HkEG9A">
As for Trump and his allies, the Department of Justice eventually has to decide whether to take the unprecedented step of indicting a former president. And if it doesn’t do so soon, the decision may be about indicting not just a former president but a <a href="https://nymag.com/intelligencer/article/donald-trump-2024-decision.html">current presidential candidate</a> as well.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="yTKaYU">
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="LMMMJx">
</p></li>
<li><strong>A deadly elementary school shooting in Uvalde, Texas</strong> -
<figure>
<img alt="US-SCHOOL-CRIME-TEXAS" src="https://cdn.vox-cdn.com/thumbor/PPcrCcHsxrHl_ofU5Dv5lTcxgNc=/249x0:4496x3185/1310x983/cdn.vox-cdn.com/uploads/chorus_image/image/70907301/1240883008.0.jpg"/>
<figcaption>
Photo by ALLISON DINNER/AFP via Getty Images
</figcaption>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Uvalde joins America’s long list of horrific school shootings.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="VOHgcn">
An 18-year-old gunman killed 19 students and two teachers at <a href="https://www.vox.com/policy-and-politics/23140441/uvalde-shooting-robb-elementary-school-texas">Robb Elementary School in Uvalde, Texas</a> on May 24, 2022.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="2Pfe9l">
It’s the deadliest US school shooting since 2018, when 17 were killed at <a href="https://www.vox.com/policy-and-politics/2018/2/14/17013596/parkland-florida-high-school-shooting">Marjory Stoneman Douglas High School in Parkland, Florida</a>, and the second-deadliest to occur at an elementary school since the 2012 shooting at <a href="https://www.vox.com/2015/12/14/10124474/sandy-hook-shooting-victims">Sandy Hook Elementary School in Newtown, Connecticut</a>.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="treEUU">
<a href="https://www.vox.com/23142734/uvalde-mass-shooting-gun-violence-control">If history is any evidence</a>, it’s unlikely that Texas Republican lawmakers, who control the state legislature and have pushed to loosen state gun laws in the lead-up to <a href="https://www.vox.com/midterm-elections-2022">the midterms,</a> will change course as a result of the Uvalde shooting.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="UF5U8F">
Follow here for all of Vox’s coverage on the latest news, political reaction, analysis, and more.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="0tZB9x">
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Odjw0T">
</p></li>
</ul>
<h1 data-aos="fade-right" id="from-the-hindu-sports">From The Hindu: Sports</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Ahead Of My Time and Arabian Phoenix excel</strong> -</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Aguila, Imperial Power, Lake Tahoe, Albinus, Domingo and Queenstown excel</strong> -</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Delayed Asian Games rescheduled to start in September 2023</strong> - The Olympic Council of Asia on Tuesday confirmed the delayed games would be held from September 23 to October 8</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Supreme Court permits advocate Harish Salve to appear virtually in BCCI matter</strong> - BCCI seeks to amend its constitution with regard to the tenure of its office bearers including its president Sourav Ganguly and secretary Jay Shah</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Harshada clinches gold at Asian Youth and Junior Weightlifting Championship</strong> - In the men's 49 kg youth event, L. Dhanush won the bronze in the snatch section with an 85 kg effort</p></li>
</ul>
<h1 data-aos="fade-right" id="from-the-hindu-national-news">From The Hindu: National News</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Lawyers’ forum demands probe into harassment of student at SIMS</strong> - Complainant had been forced to withdraw the case, it alleged</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Rains recede in Malnad</strong> -</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Saji Cherian attempts to put speech controversy to rest</strong> - Former Minister makes a statement in the Assembly under rule 64</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>LeT module brings 4 terrorists from Kashmir to Pir Panjal area in Jammu; teams dispatched for crackdown</strong> - The security forces unearthed this information while interrogating the members of the twin modules busted by the police in Rajouri recently</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Opposition playing ‘flood politics’</strong> - They have failed to help people in need: Harish</p></li>
</ul>
<h1 data-aos="fade-right" id="from-bbc-europe">From BBC: Europe</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Heatwave: Ferocious European heat heads north</strong> - As deadly wildfires rage in several European countries, provisional figures show a new UK heat record.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Ukraine war: Putin to visit Iran in rare international trip</strong> - Russia’s leader has confined his trips to the former USSR since the invasion of Ukraine in February.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Heatwave: Forest fires continue in France</strong> - French firefighters are working to keep wildfires in the south-west of the country under control.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Daria Kasatkina: Russian calls for end to war and criticises country’s attitude to homosexuality</strong> - Russian tennis player Daria Kasatkina criticises her country’s attitude to homosexuality after coming out as gay and also calls for an end to the war in Ukraine.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Claes Oldenburg: Radical pop art sculptor dies at 93</strong> - The Swedish-born artist famous for making giant works of everyday objects dies in New York City.</p></li>
</ul>
<h1 data-aos="fade-right" id="from-ars-technica">From Ars Technica</h1>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Cryptomining boom has people’s energy bills skyrocketing; feds mull new rules</strong> - No major US cryptominers said they track energy use impacts on local residents. - <a href="https://arstechnica.com/?p=1867655">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>AI art is challenging the boundaries of curation</strong> - Artists working with programs like DALL-E do more than push a button. - <a href="https://arstechnica.com/?p=1867634">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Servers running Digium Phones VoiP software are getting backdoored</strong> - More than 500,000 malicious samples seen in campaign that installs web shells. - <a href="https://arstechnica.com/?p=1867630">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Google Wallet rolls out to users, will live alongside Google Pay in the US</strong> - Google will have one payment app internationally, but not in the US, for some reason. - <a href="https://arstechnica.com/?p=1867564">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The MacBook Pro will get the M2 treatment as soon as this fall</strong> - M2 Pro and M2 Max will reportedly focus mostly on graphics improvements. - <a href="https://arstechnica.com/?p=1867596">link</a></p></li>
</ul>
<h1 data-aos="fade-right" id="from-jokes-subreddit">From Jokes Subreddit</h1>
<ul>
<li><strong>So I was having sex with my girlfriend at her parent’s house…</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
and we were really getting it on with her moaning and groaning which woke up her dad. We were really in the heat of it so we never noticed when he walked upstairs and then walked in on us.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
“Dad!” my girlfriend exclaimed in a panic “I…I’m sorry”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The dad being, a dad, replies “Hi sorry, I’m Dad!”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
He then turns to me and asks “Are you fucking sorry?”
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/Remarkable-Youth-504"> /u/Remarkable-Youth-504 </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/w2gd63/so_i_was_having_sex_with_my_girlfriend_at_her/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/w2gd63/so_i_was_having_sex_with_my_girlfriend_at_her/">[comments]</a></span></p></li>
<li><strong>A married man was having an affair with his secretary.</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
One day, their passions overcame them in the office and they took off for her house.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Exhausted from the afternoon’s activities, they fell asleep and awoke at around 8 p.m. As the man threw on his clothes, he told the woman to take his shoes outside and rub them through the grass and dirt.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Confused, she nonetheless complied and he slipped into his shoes and drove home. “Where have you been?” demanded his wife when he entered the house. “Darling,” replied the man, “I can’t lie to you. I’ve been having an affair with my secretary. I fell asleep in her bed and didn’t wake up until eight o’clock.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The wife glanced down at his shoes and said, “You liar! You’ve been playing golf!”
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/Remarkable-Youth-504"> /u/Remarkable-Youth-504 </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/w2gcie/a_married_man_was_having_an_affair_with_his/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/w2gcie/a_married_man_was_having_an_affair_with_his/">[comments]</a></span></p></li>
<li><strong>A Priest working in a remote parish in Greenland gets his yearly visit from his Bishop.</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The Bishop asks him, “How are you managing with the loneliness?”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The Priest responds, " If it wasn’t for my Rosary and my whiskey, I couldn’t make it. Would you like a shot of whiskey?"
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The Bishop nods his head yes.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The Priest yells out, “Hey Rosary, bring us two shots of whisky”
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/marycartlizer"> /u/marycartlizer </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/w27xvg/a_priest_working_in_a_remote_parish_in_greenland/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/w27xvg/a_priest_working_in_a_remote_parish_in_greenland/">[comments]</a></span></p></li>
<li><strong>A police officer pulled me over</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
He walked up to my car and said, “Papers?” to which I replied “Scissors, I win!” and drove off.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
I think he wants a rematch because he’s been following me for an hour.
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/PR0CR45T184T0R"> /u/PR0CR45T184T0R </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/w2eyez/a_police_officer_pulled_me_over/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/w2eyez/a_police_officer_pulled_me_over/">[comments]</a></span></p></li>
<li><strong>My wife and I have an open relationship</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Found out last night
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/TapiocaTuesday"> /u/TapiocaTuesday </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/w23ljs/my_wife_and_i_have_an_open_relationship/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/w23ljs/my_wife_and_i_have_an_open_relationship/">[comments]</a></span></p></li>
</ul>
<script>AOS.init();</script></body></html>

4
index.html
View File

File diff suppressed because one or more lines are too long